EuroIntervention | Your reference journal for coronary, valvular and structural interventions

Your reference journal for coronary, valvular and structural interventions

State-of-the-Art

Dec 8

Ziad A. Ali, Doosup Shin, et al.

Calcified nodules (CNs) pose challenges in percutaneous coronary intervention (PCI) due to their complex morphology and variable treatment responses. CNs are classified into eruptive and non-eruptive subtypes, with distinct features and prognostic implications.

free

Editorial

Dec 5

Beta blockers after MI still relevant for many

Johanne Silvain, Niki Procopi

A meta-analysis of 23,531 post-MI patients found that beta blocker use may only provide a modest morbidity reduction, and withdrawal may be safe for some, but continuation remains relevant for most post-MI patients.

Beta blockers after MI still relevant for many

free

Original Research

Dec 3

Beta blocker withholding/withdrawal after MI

Xavier Rossello, Borja Ibanez, et al.

In patients with myocardial infarction and LVEF >40%, beta blocker withholding or withdrawal at discharge was not associated with increased short-term or recurrent ischaemic events.

Beta blocker withholding/withdrawal after MI

open access

State-of-the-Art

Dec 2

Management of NSTE-ACS

Mila Kovacevic, Vijay Kunadian, et al.

This review provides a comprehensive overview of current evidence-based approaches to the management of non-ST-segment elevation acute coronary syndrome, focusing on diagnosis, risk stratification, and treatment strategies.

free

new issue

Dec 1

A new issue of EuroIntervention

State-of-the-Art on the management of NSTE-ACS; State-of-the-Art on calcified nodules and PCI; beta blockers after MI; abbreviated antiplatelet therapy in HBR patients with CKD; thrombosis after Reducer migration

letter to the editor

Nov 27

Letter: TAVI and covert brain injury

Nikolaos Pyrpyris, Konstantinos Tsioufis, et al.

This letter discusses the need to evaluate the addition of novel pharmacotherapy to current regimens in order to improve outcomes related to leaflet thrombosis and cerebral injury after TAVI procedures.

free

letter to the editor

Nov 27

Reply: TAVI and covert brain injury

Victor Alfonso Jimenez Diaz, Paula Bellas Lamas, et al.

The reply adresses the need for further research on optimal post-TAVI regimens to balance ischaemic, embolic, bleeding, and cognitive risks, and the prevention of covert brain injury in the TAVI population.

free

Turning Point Podcast

Listen now

Flashlight

Dec 1

Thrombosis after Reducer migration

Leonardo Portolan, Giovanni Luigi De Maria, et al.

This case report describes the successful implantation of a double coronary sinus Reducer device in a patient with refractory angina, complicated by proximal migration of the initial Reducer and subsequent coronary sinus thrombosis detected by cardiac CT.

Original Research

Nov 26

Coronary cannulation after Evolut FX

Yohei Ohno, Guilherme F. Attizzani, et al.

The study found that coronary cannulation after TAVI with the Evolut FX valve was highly feasible due to a high rate of commissural and coronary alignment, but coronary misalignment was the strongest predictor of suboptimal coronary cannulation for both the left and right coronary arteries.

Editorial

Nov 26

TAV alignment: progress and remaining gaps

Ignacio J. Amat-Santos, Filippo Pensotti

This study demonstrates high coronary cannulation success rates with new-generation transcatheter heart valves, but moderate-to-severe coronary misalignment remains a concern that requires dedicated procedural strategies or device designs.

TAV alignment: progress and remaining gaps

free

Expert Consensus

Nov 25

TTVI patients undergoing TAVI

Jean-Claude Deharo, Fabien Praz, et al.

This scientific statement provides guidance on the management of patients with cardiac implantable electronic device leads crossing the tricuspid valve who are undergoing transcatheter tricuspid valve interventions.

Viewpoint

Nov 24

ACURATE platform discontinuation

Won-Keun Kim, Helge Möllmann

The ACURATE transcatheter heart valve platform was discontinued by Boston Scientific in 2025 due to disappointing results in the randomized IDE trial with the ACURATE neo2 valve, preceded by negative outcomes in the SCOPE I and SCOPE II trials with the first-generation ACURATE neo valve.

free

Original Research

Nov 21

The TRICURE first-in-human study

Emmanuel Teiger, Julien Dreyfus, et al.

The TRICURE first-in-human study evaluated a novel transcatheter tricuspid valve replacement system, demonstrating the feasibility and safety of the device, with successful elimination of tricuspid regurgitation in all patients.

open access

Original Research

Nov 20

HALT following TAVI using S3UR

Kenichi Ishizu, Kentaro Hayashida, et al.

This study found that hypoattenuating leaflet thickening (HALT) was detected in 21.3% of patients 30 days after transcatheter aortic valve implantation with the latest-generation SAPIEN 3 Ultra RESILIA THV. Hourglass-shaped THV frame and asymmetric leaflet expansion were associated with increased HALT risk.